Cargando…

Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion

PURPOSE: To search for the utility of DCE-MRP to differentiate between posttreatment enhancement (PT) and tumoral enhancement (TM) in high-grade glial tumors. MATERIALS AND METHODS: Thirty-four patients with glioma (11 grade 3; 23 grade 4) were enrolled. Enhancement in the vicinity of the resection...

Descripción completa

Detalles Bibliográficos
Autores principales: Dündar, Tolga Turan, Cetinkaya, Ezra, Yurtsever, İsmail, Uysal, Ömer, Aralaşmak, Ayşe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825574/
https://www.ncbi.nlm.nih.gov/pubmed/35185410
http://dx.doi.org/10.1155/2022/6948422
_version_ 1784647244427821056
author Dündar, Tolga Turan
Cetinkaya, Ezra
Yurtsever, İsmail
Uysal, Ömer
Aralaşmak, Ayşe
author_facet Dündar, Tolga Turan
Cetinkaya, Ezra
Yurtsever, İsmail
Uysal, Ömer
Aralaşmak, Ayşe
author_sort Dündar, Tolga Turan
collection PubMed
description PURPOSE: To search for the utility of DCE-MRP to differentiate between posttreatment enhancement (PT) and tumoral enhancement (TM) in high-grade glial tumors. MATERIALS AND METHODS: Thirty-four patients with glioma (11 grade 3; 23 grade 4) were enrolled. Enhancement in the vicinity of the resection cavity demonstrated by DCE-MRP was taken into consideration. Based on the follow-up scans, reoperation or biopsy results, the enhancement type was categorized as PT or TM. Measurements were performed at the enhancing area near the resection cavity (ERC), nearby (NNA) and contralateral nonenhancing areas (CLNA). Perfusion parameters of the ERC were also subtracted from NNA and CLNA. Intragroup comparison (paired sample t-test) and intergroup comparison (Student's t-test) were made. RESULTS: There were 7 PTs and 27 TMs. In the PT, the subtracted values of Ve and IAUC from the CLNA and NNA and the subtracted value of Kep from NNA were statistically different. In TM, all metrics were significantly different comparing the CLNA and NNA. Comparing PT with TM, Ktrans, IAUC, Kep, and subtracted values of Ktrans and IAUC from both NNA and CLNA were significantly different. CONCLUSIONS: In PT, only Ktrans values did not reveal any difference comparing NNA and CLNA. To differentiate PT from TM, Ktrans, Kep, IAUC, and subtracted values of Ktrans and IAUC from NNA and CLNA can be used. These findings are in concordance with literature.
format Online
Article
Text
id pubmed-8825574
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88255742022-02-18 Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion Dündar, Tolga Turan Cetinkaya, Ezra Yurtsever, İsmail Uysal, Ömer Aralaşmak, Ayşe Contrast Media Mol Imaging Research Article PURPOSE: To search for the utility of DCE-MRP to differentiate between posttreatment enhancement (PT) and tumoral enhancement (TM) in high-grade glial tumors. MATERIALS AND METHODS: Thirty-four patients with glioma (11 grade 3; 23 grade 4) were enrolled. Enhancement in the vicinity of the resection cavity demonstrated by DCE-MRP was taken into consideration. Based on the follow-up scans, reoperation or biopsy results, the enhancement type was categorized as PT or TM. Measurements were performed at the enhancing area near the resection cavity (ERC), nearby (NNA) and contralateral nonenhancing areas (CLNA). Perfusion parameters of the ERC were also subtracted from NNA and CLNA. Intragroup comparison (paired sample t-test) and intergroup comparison (Student's t-test) were made. RESULTS: There were 7 PTs and 27 TMs. In the PT, the subtracted values of Ve and IAUC from the CLNA and NNA and the subtracted value of Kep from NNA were statistically different. In TM, all metrics were significantly different comparing the CLNA and NNA. Comparing PT with TM, Ktrans, IAUC, Kep, and subtracted values of Ktrans and IAUC from both NNA and CLNA were significantly different. CONCLUSIONS: In PT, only Ktrans values did not reveal any difference comparing NNA and CLNA. To differentiate PT from TM, Ktrans, Kep, IAUC, and subtracted values of Ktrans and IAUC from NNA and CLNA can be used. These findings are in concordance with literature. Hindawi 2022-02-01 /pmc/articles/PMC8825574/ /pubmed/35185410 http://dx.doi.org/10.1155/2022/6948422 Text en Copyright © 2022 Tolga Turan Dündar et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dündar, Tolga Turan
Cetinkaya, Ezra
Yurtsever, İsmail
Uysal, Ömer
Aralaşmak, Ayşe
Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title_full Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title_fullStr Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title_full_unstemmed Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title_short Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion
title_sort follow-up of high-grade glial tumor; differentiation of posttreatment enhancement and tumoral enhancement by dce-mr perfusion
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825574/
https://www.ncbi.nlm.nih.gov/pubmed/35185410
http://dx.doi.org/10.1155/2022/6948422
work_keys_str_mv AT dundartolgaturan followupofhighgradeglialtumordifferentiationofposttreatmentenhancementandtumoralenhancementbydcemrperfusion
AT cetinkayaezra followupofhighgradeglialtumordifferentiationofposttreatmentenhancementandtumoralenhancementbydcemrperfusion
AT yurtseverismail followupofhighgradeglialtumordifferentiationofposttreatmentenhancementandtumoralenhancementbydcemrperfusion
AT uysalomer followupofhighgradeglialtumordifferentiationofposttreatmentenhancementandtumoralenhancementbydcemrperfusion
AT aralasmakayse followupofhighgradeglialtumordifferentiationofposttreatmentenhancementandtumoralenhancementbydcemrperfusion